Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Average Rating of “Hold” by Brokerages

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have received an average recommendation of “Hold” from the twenty-three analysts that are currently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $102.80.

A number of analysts have weighed in on the stock. JPMorgan Chase & Co. decreased their target price on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a research report on Wednesday, April 29th. Citizens Jmp decreased their target price on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a research report on Wednesday, April 29th. TD Cowen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Monday, January 26th. Robert W. Baird set a $92.00 target price on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Finally, BTIG Research reissued a “neutral” rating on shares of Zimmer Biomet in a research report on Monday, March 23rd.

Zimmer Biomet Stock Up 1.2%

Shares of NYSE ZBH opened at $86.13 on Wednesday. The company has a 50 day simple moving average of $89.27 and a 200 day simple moving average of $91.23. The firm has a market cap of $16.66 billion, a PE ratio of 22.37, a price-to-earnings-growth ratio of 1.97 and a beta of 0.48. Zimmer Biomet has a 1 year low of $79.12 and a 1 year high of $108.29. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. The business had revenue of $2.09 billion during the quarter, compared to analyst estimates of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter last year, the business earned $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, research analysts forecast that Zimmer Biomet will post 8.47 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st were given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend was Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 24.94%.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the sale, the senior vice president owned 10,224 shares of the company’s stock, valued at approximately $967,803.84. This represents a 20.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.28% of the company’s stock.

Institutional Trading of Zimmer Biomet

Several large investors have recently modified their holdings of the stock. Bank of America Corp DE grew its position in shares of Zimmer Biomet by 19.2% during the 1st quarter. Bank of America Corp DE now owns 1,549,790 shares of the medical equipment provider’s stock worth $140,132,000 after buying an additional 249,175 shares during the period. Hamilton Wealth LLC acquired a new stake in shares of Zimmer Biomet during the 1st quarter worth approximately $678,000. Edgestream Partners L.P. grew its position in shares of Zimmer Biomet by 365.3% during the 1st quarter. Edgestream Partners L.P. now owns 13,469 shares of the medical equipment provider’s stock worth $1,218,000 after buying an additional 10,574 shares during the period. Kentucky Retirement Systems grew its position in shares of Zimmer Biomet by 13.5% during the 1st quarter. Kentucky Retirement Systems now owns 14,116 shares of the medical equipment provider’s stock worth $1,315,000 after buying an additional 1,683 shares during the period. Finally, South Dakota Investment Council grew its position in shares of Zimmer Biomet by 1.5% during the 1st quarter. South Dakota Investment Council now owns 187,504 shares of the medical equipment provider’s stock worth $16,954,000 after buying an additional 2,760 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.